Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Smoking cessation intervention for reducing disease activity in chronic autoimmune inflammatory joint diseases.

Roelsgaard IK, Esbensen BA, Østergaard M, Rollefstad S, Semb AG, Christensen R, Thomsen T.

Cochrane Database Syst Rev. 2019 Sep 2;9:CD012958. doi: 10.1002/14651858.CD012958.pub2.

PMID:
31476270
2.

Response to: "Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients" by Fornaro et al.

Agca R, Heslinga SC, Rollefstad S, Heslinga S, Södergren A, Semb AG, Kitas GD, Sattar N, Nurmohamed MT; EULAR task force “EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update”.

Ann Rheum Dis. 2019 Aug 14. pii: annrheumdis-2019-215748. doi: 10.1136/annrheumdis-2019-215748. [Epub ahead of print] No abstract available.

PMID:
31413003
3.

Biomarkers of cardiovascular risk across phenotypes of osteoarthritis.

Provan SA, Rollefstad S, Ikdahl E, Mathiessen A, Berg IJ, Eeg I, Wilkinson IB, McEniery CM, Kvien TK, Hammer HB, Østerås N, Haugen IK, Semb AG.

BMC Rheumatol. 2019 Aug 8;3:33. doi: 10.1186/s41927-019-0081-8. eCollection 2019.

4.

High intensity exercise for 3 months reduces disease activity in axial spondyloarthritis (axSpA): a multicentre randomised trial of 100 patients.

Sveaas SH, Bilberg A, Berg IJ, Provan SA, Rollefstad S, Semb AG, Hagen KB, Johansen MW, Pedersen E, Dagfinrud H.

Br J Sports Med. 2019 Feb 11. pii: bjsports-2018-099943. doi: 10.1136/bjsports-2018-099943. [Epub ahead of print]

PMID:
30745314
5.

Feasibility of cardiovascular disease risk assessments in rheumatology outpatient clinics: experiences from the nationwide NOCAR project.

Ikdahl E, Rollefstad S, Wibetoe G, Salberg A, Krøll F, Bergsmark K, Kvien TK, Olsen IC, Soldal DM, Bakland G, Lexberg Å, Gjesdal CG, Gulseth C, Haugeberg G, Semb AG.

RMD Open. 2018 Oct 1;4(2):e000737. doi: 10.1136/rmdopen-2018-000737. eCollection 2018.

6.

Left Ventricular Systolic Myocardial Function in Ankylosing Spondylitis.

Midtbø H, Semb AG, Matre K, Rollefstad S, Berg IJ, Gerdts E.

Arthritis Care Res (Hoboken). 2019 Sep;71(9):1276-1283. doi: 10.1002/acr.23765. Epub 2019 Aug 7.

PMID:
30242984
7.

The effect of brief versus individually tailored dietary advice on change in diet, lipids and blood pressure in patients with inflammatory joint disease.

Fagerhøi MG, Rollefstad S, Olsen SU, Semb AG.

Food Nutr Res. 2018 Sep 4;62. doi: 10.29219/fnr.v62.1512. eCollection 2018.

8.

Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases.

Ikdahl E, Wibetoe G, Rollefstad S, Salberg A, Bergsmark K, Kvien TK, Olsen IC, Soldal DM, Bakland G, Lexberg Å, Fevang BTS, Gulseth HC, Haugeberg G, Semb AG.

Int J Cardiol. 2019 Jan 1;274:311-318. doi: 10.1016/j.ijcard.2018.06.111. Epub 2018 Jul 2.

PMID:
30007486
9.

Ankylosing Spondylitis Is Associated with Increased Prevalence of Left Ventricular Hypertrophy.

Midtbø H, Gerdts E, Berg IJ, Rollefstad S, Jonsson R, Semb AG.

J Rheumatol. 2018 Aug;45(9):1249-1255. doi: 10.3899/jrheum.171124. Epub 2018 Jun 1.

PMID:
29858235
10.

Optimization of CVD prevention in psoriatic arthritis.

Semb AG, Rollefstad S.

Nat Rev Rheumatol. 2018 Jun;14(6):323-324. doi: 10.1038/s41584-018-0002-z. No abstract available.

PMID:
29686327
11.

Change in cardiovascular risk factors in patients who develop psoriatic arthritis: longitudinal data from the Nord-Trøndelag Health Study (HUNT).

Gulati AM, Salvesen Ø, Thomsen RS, Kavanaugh A, Semb AG, Rollefstad S, Haugeberg G, Hoff M.

RMD Open. 2018 Mar 14;4(1):e000630. doi: 10.1136/rmdopen-2017-000630. eCollection 2018.

12.

Discrepancies in risk age and relative risk estimations of cardiovascular disease in patients with inflammatory joint diseases.

Wibetoe G, Ikdahl E, Rollefstad S, Olsen IC, Bergsmark K, Kvien TK, Salberg A, Soldal DM, Bakland G, Lexberg Å, Fevang BT, Gulseth HC, Haugeberg G, Semb AG.

Int J Cardiol. 2018 Feb 1;252:201-206. doi: 10.1016/j.ijcard.2017.10.038.

PMID:
29249429
13.

The effect of an intensive smoking cessation intervention on disease activity in patients with rheumatoid arthritis: study protocol for a randomised controlled trial.

Roelsgaard IK, Thomsen T, Østergaard M, Christensen R, Hetland ML, Jacobsen S, Andersen L, Tønnesen H, Rollefstad S, Semb AG, Esbensen BA.

Trials. 2017 Nov 28;18(1):570. doi: 10.1186/s13063-017-2309-5.

14.

Associations between coronary and carotid artery atherosclerosis in patients with inflammatory joint diseases.

Svanteson M, Rollefstad S, Kløw NE, Hisdal J, Ikdahl E, Semb AG, Haig Y.

RMD Open. 2017 Sep 17;3(2):e000544. doi: 10.1136/rmdopen-2017-000544. eCollection 2017.

15.

Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis.

Crowson CS, Rollefstad S, Ikdahl E, Kitas GD, van Riel PLCM, Gabriel SE, Matteson EL, Kvien TK, Douglas K, Sandoo A, Arts E, Wållberg-Jonsson S, Innala L, Karpouzas G, Dessein PH, Tsang L, El-Gabalawy H, Hitchon C, Ramos VP, Yáñez IC, Sfikakis PP, Zampeli E, Gonzalez-Gay MA, Corrales A, Laar MV, Vonkeman HE, Meek I, Semb AG; A Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA).

Ann Rheum Dis. 2018 Jan;77(1):48-54. doi: 10.1136/annrheumdis-2017-211735. Epub 2017 Sep 6.

16.

Cardiovascular disease risk profiles in inflammatory joint disease entities.

Wibetoe G, Ikdahl E, Rollefstad S, Olsen IC, Bergsmark K, Kvien TK, Salberg A, Soldal DM, Bakland G, Lexberg Å, Fevang BT, Gulseth HC, Haugeberg G, Semb AG.

Arthritis Res Ther. 2017 Jul 3;19(1):153. doi: 10.1186/s13075-017-1358-1.

17.

Correction: Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis.

Crowson CS, Rollefstad S, Kitas GD, van Riel PL, Gabriel SE, Semb AG; A Trans-Atlantic Cardiovascular Risk Consortium for Rheumatoid Arthritis (ATACC-RA).

PLoS One. 2017 Apr 7;12(4):e0175605. doi: 10.1371/journal.pone.0175605. eCollection 2017.

18.

Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis.

Crowson CS, Rollefstad S, Kitas GD, van Riel PL, Gabriel SE, Semb AG; A Trans-Atlantic Cardiovascular Risk Consortium for Rheumatoid Arthritis (ATACC-RA).

PLoS One. 2017 Mar 23;12(3):e0174656. doi: 10.1371/journal.pone.0174656. eCollection 2017. Erratum in: PLoS One. 2017 Apr 7;12 (4):e0175605.

19.

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.

Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT.

Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775. Epub 2016 Oct 3. Review.

PMID:
27697765
20.

Exploring cardiovascular disease risk evaluation in patients with inflammatory joint diseases.

Semb AG, Ikdahl E, Hisdal J, Olsen IC, Rollefstad S.

Int J Cardiol. 2016 Nov 15;223:331-336. doi: 10.1016/j.ijcard.2016.08.129. Epub 2016 Aug 7.

PMID:
27543704
21.

Spondyloarthropathies: CVD prevention and statin therapy in ankylosing spondylitis.

Semb AG, Rollefstad S.

Nat Rev Rheumatol. 2016 Aug;12(8):441-2. doi: 10.1038/nrrheum.2016.103. Epub 2016 Jun 30. No abstract available.

PMID:
27357255
22.

Predictive Value of Arterial Stiffness and Subclinical Carotid Atherosclerosis for Cardiovascular Disease in Patients with Rheumatoid Arthritis.

Ikdahl E, Rollefstad S, Wibetoe G, Olsen IC, Berg IJ, Hisdal J, Uhlig T, Haugeberg G, Kvien TK, Provan SA, Semb AG.

J Rheumatol. 2016 Sep;43(9):1622-30. doi: 10.3899/jrheum.160053. Epub 2016 Jun 15.

PMID:
27307523
23.

The association of hypertension with asymptomatic cardiovascular organ damage in rheumatoid arthritis.

Midtbø H, Gerdts E, Kvien TK, Olsen IC, Lønnebakken MT, Davidsen ES, Rollefstad S, Semb AG.

Blood Press. 2016 Oct;25(5):298-304. doi: 10.3109/08037051.2016.1172867. Epub 2016 Apr 28.

PMID:
27123584
24.

Sustained Improvement of Arterial Stiffness and Blood Pressure after Long-Term Rosuvastatin Treatment in Patients with Inflammatory Joint Diseases: Results from the RORA-AS Study.

Ikdahl E, Rollefstad S, Hisdal J, Olsen IC, Pedersen TR, Kvien TK, Semb AG.

PLoS One. 2016 Apr 19;11(4):e0153440. doi: 10.1371/journal.pone.0153440. eCollection 2016.

25.

Chronic kidney disease reduces risk of cardiovascular disease in patients with rheumatoid arthritis according to the QRISK lifetime cardiovascular risk calculator.

Ikdahl E, Rollefstad S, Wibetoe G, Semb AG.

Rheumatology (Oxford). 2016 Aug;55(8):1528-9. doi: 10.1093/rheumatology/kew002. Epub 2016 Feb 8. No abstract available.

PMID:
26857077
26.

Association of Chest Pain and Risk of Cardiovascular Disease with Coronary Atherosclerosis in Patients with Inflammatory Joint Diseases.

Rollefstad S, Ikdahl E, Hisdal J, Kvien TK, Pedersen TR, Semb AG.

Front Med (Lausanne). 2015 Nov 10;2:80. doi: 10.3389/fmed.2015.00080. eCollection 2015.

27.

Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study.

Ikdahl E, Hisdal J, Rollefstad S, Olsen IC, Kvien TK, Pedersen TR, Semb AG.

Arthritis Res Ther. 2015 Oct 8;17:279. doi: 10.1186/s13075-015-0795-y.

28.

EULAR task force recommendations on annual cardiovascular risk assessment for patients with rheumatoid arthritis: an audit of the success of implementation in a rheumatology outpatient clinic.

Ikdahl E, Rollefstad S, Olsen IC, Kvien TK, Hansen IJ, Soldal DM, Haugeberg G, Semb AG.

Biomed Res Int. 2015;2015:515280. doi: 10.1155/2015/515280. Epub 2015 Mar 1.

29.

On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study.

Gulati AM, Semb AG, Rollefstad S, Romundstad PR, Kavanaugh A, Gulati S, Haugeberg G, Hoff M.

Ann Rheum Dis. 2016 May;75(5):819-24. doi: 10.1136/annrheumdis-2014-206824. Epub 2015 Mar 26.

PMID:
25814652
30.

Rosuvastatin-Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study.

Rollefstad S, Ikdahl E, Hisdal J, Olsen IC, Holme I, Hammer HB, Smerud KT, Kitas GD, Pedersen TR, Kvien TK, Semb AG.

Arthritis Rheumatol. 2015 Jul;67(7):1718-28. doi: 10.1002/art.39114.

31.

Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms.

Arts EE, Popa CD, Den Broeder AA, Donders R, Sandoo A, Toms T, Rollefstad S, Ikdahl E, Semb AG, Kitas GD, Van Riel PL, Fransen J.

Ann Rheum Dis. 2016 Apr;75(4):674-80. doi: 10.1136/annrheumdis-2014-206879. Epub 2015 Feb 17.

PMID:
25691119
32.

Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention.

Rollefstad S, Ikdahl E, Hisdal J, Kvien TK, Pedersen TR, Holme I, Semb AG.

Ann Rheum Dis. 2015 Aug;74(8):1544-50. doi: 10.1136/annrheumdis-2013-204636. Epub 2014 Apr 3.

PMID:
24699940
33.

Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice.

Semb AG, Rollefstad S, van Riel P, Kitas GD, Matteson EL, Gabriel SE.

Ann Rheum Dis. 2014 Jul;73(7):1284-8. doi: 10.1136/annrheumdis-2013-204792. Epub 2014 Mar 7.

PMID:
24608403
34.

Hand, hip and knee osteoarthritis in a Norwegian population-based study--the MUST protocol.

Østerås N, Risberg MA, Kvien TK, Engebretsen L, Nordsletten L, Bruusgaard D, Schjervheim UB, Haugen IK, Hammer HB, Provan S, Øiestad BE, Semb AG, Rollefstad S, Hagen KB, Uhlig T, Slatkowsky-Christensen B, Kjeken I, Flugsrud G, Grotle M, Sesseng S, Edvardsen H, Natvig B.

BMC Musculoskelet Disord. 2013 Jul 5;14:201. doi: 10.1186/1471-2474-14-201.

35.

Carotid plaque characteristics and disease activity in rheumatoid arthritis.

Semb AG, Rollefstad S, Provan SA, Kvien TK, Stranden E, Olsen IC, Hisdal J.

J Rheumatol. 2013 Apr;40(4):359-68. doi: 10.3899/jrheum.120621. Epub 2013 Jan 15.

PMID:
23322468
36.

Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic.

Rollefstad S, Kvien TK, Holme I, Eirheim AS, Pedersen TR, Semb AG.

Ann Rheum Dis. 2013 Dec;72(12):1968-74. doi: 10.1136/annrheumdis-2012-202789. Epub 2012 Dec 22.

PMID:
23264359

Supplemental Content

Loading ...
Support Center